Background. Infection is a common complication of ventricular-assist devices (VADs) and is associated with rehospitalization, thromboembolic events, VAD malfunction, delay in heart transplantation, and a high mortality rate. The objectives of this study were to investigate the frequency of fungal VAD infections and assess various risk factors and their effects on mortality as compared with bacterial VAD infections.
hood of rehospitalization, thromboembolic events, VAD malfunction requiring multiple revisions, delay in heart transplantation, and removal or exchange of the infected device [3, 4] . The need to remove the infected VAD is attributed to the presence of infecting organisms within the biofilm, which comprises a complex population of slowly multiplying organisms and their products as well as host elements that include platelets and host tissue ligands. Not only does the biofilm provide a barrier to host defense mechanisms (leukocytes, antibodies, and complement), but it also can impair the penetration and/or the activity of antimicrobial agents. In that regard, the minimum inhibitory concentration of some antibiotics are up to 500 times higher for bacteria embedded within the biofilm matrix than their planktonic (free-floating) counterpart [5] [6] [7] .
The main pathogenesis of VAD infection has invariably focused on the driveline (percutaneous tunnel for VAD power cables) as the port of entry for organisms, which then migrate via this conduit into subcutaneous tissues and the pump site, leading to pocket infection. This can result in infection of the pump housing, pump inflow, outflow tracts, and/or the bloodstream, and eventually cause a disseminated infection. Alternatively, the pump inflow and outflow tracts may be hematogenously infected, as is the case with endocarditis [8] . The most common organisms associated with VAD infection are gram-positive bacteria, particularly the staphylococci, which are responsible for 57% of all VAD-related infections and 62% of all VAD-related bloodstream infections. Other causes of VAD infections include Pseudomonas aeruginosa, Escherichia coli, and enterococci. Candida infections are less frequent but are responsible for the highest mortality rates [8, 9] . Infection of the VAD is the most common cause of death among patients who require this device for longterm mechanical circulatory support [10] . There is substantial literature describing VAD infections, but most of these describe bacterial VAD infections. There is very little data describing fungal VAD infections and none comparing the risk factors and outcomes to those of bacterial VAD infections. The main goals of this study were to investigate the frequency of fungal VAD infections in the era of broad-spectrum prophylactic antimicrobial use, assess risk factors for infection, and compare the outcomes of fungal versus bacterial VAD infections.
METHODS

Study design.
We performed a retrospective chart review of all patients that had received a VAD at Saint Luke's Episcopal Hospital in Houston, Texas from January 1992 through De- NOTE. Data are no (%) of patients, unless otherwise indicated. Laboratory data refers to data recorded on the day of diagnosis of VAD infection. Temperature refers to the maximum temperature within 24 h of the diagnosis of VAD infection. Types of infections included all sites, and thus, the percentages total 1100%. All comparisons, except for the following, remained similar in statistical significance when analysis was repeated with a modified fungal group that excluded 7 patients who had a preceding bacterial VAD infection prior to development of a fungal VAD infection: delayed chest wall closure, abdominal surgery, and driveline infections. AICD, automatic implantable cardioverter defibrillator; IQR, interquartile range; SD, standard deviation; WBC, white blood cell.
a Defined as a body mass index (calculated as weight in kilograms divided by the square of height in meters) 130. NOTE. Data are no (%) of patients, unless otherwise indicated. All comparisons, except for number of VAD infections, remained similar in statistical significance when analysis was repeated with a modified fungal group that excluded 7 patients who had a preceding bacterial VAD infection prior to development of a fungal VAD infection. cember 2007. The study was approved by the Institutional Review Boards of Baylor College of Medicine and Saint Luke's Episcopal Hospital, which determined that patients' informed consent was not required.
Patient information. Information was collected only from patients who developed a VAD infection and included demographic characteristics (age, sex, and race), presence of comorbidities, underlying cardiomyopathy, use of preoperative antimicrobial prophylaxis, type of implanted VAD, operative data, type of VAD infection, non-VAD infections, hospital course, pertinent laboratory data, and results of microbiological tests. Data was collected from the time of admission for VAD implantation to last outpatient/inpatient follow-up or death.
VAD recipients received perioperative antibiotics that generally consisted of vancomycin and cefepime. After 2000, fluconazole was added to the antibiotic regimen. The duration of postoperative antimicrobial prophylaxis was variable and the decision to discontinue antimicrobial prophylaxis was made by the surgical and infectious disease teams. After discharge, patients were followed weekly in the clinic. Care of the driveline exit site consisted of daily cleansing with chlorhexidine/iodine solution and placement of an occlusive dressing. All patients who developed symptoms and/or signs of infection were evaluated to identify the source of infection. Pertinent cultures were obtained from the driveline exit site, and if indicated, blood cultures were obtained. Samples were also sent for culture if surgical drainage was performed. Imaging of the pocket site with ultrasound or computed tomography was also performed as needed.
Definitions of outcomes. VAD infections were classified into the following 4 categories: (1) driveline infection was defined as the presence of purulent drainage from the driveline exit site and isolation of at least one pathogen from this site, (2) pocket infection was defined by a fluid collection around the ventricular pump which was detected on imaging studies and at least one pathogen isolated from that fluid collection, (3) VAD-related bloodstream infection was defined as either the isolation of the same microorganism from more than 1 set of blood cultures and from the driveline exit site and/or the VAD pocket, or the presence of more than one positive blood culture with no evidence for another source of infection besides the ventricular device, and, (4) VAD-related infective endocarditis was defined clinically as the isolation of 1 or more organisms from 11 set of blood cultures associated with the development of 1 or more embolic events. Although most patients had histopathologic evidence of infection of the inflow/ outflow conduits of the explanted ventricular device, these findings were not a requisite for the diagnosis of VAD-related infective endocarditis.
If a patient had a fungal isolate that was related to the VAD, that patient was counted in the fungal infection category. Patients in the bacterial infection category had a purely bacterial infection. Among patients with multiple bacterial infections, only the first episode was considered for analysis. Clinical cure was defined as resolution of the clinical features of a VAD infection. Microbiological cure meant that repeat cultures following clinical resolution of the VAD infection were negative. Recurrence was defined as growth of an identical organism with the same antimicrobial susceptibility pattern as the organism that caused the initial VAD infection at any time following clinical resolution of that first infection.
Statistical analysis. Categorical variables were evaluated by using univariate analysis (x 2 or Fisher's exact test, as appropriate) and multivariate logistic regression analysis. Continuous variables were compared by using a Student's t test. A 2-tailed P value !.05 was considered to be significant. For survival analysis, the groups were compared by performing a log-rank test on the Kaplan-Meier estimates. Data were analyzed using SAS, version 9.2 (SAS Institute), and Stata, version 8.2 (Statacorp).
RESULTS
Patients.
We identified 476 patients who underwent VAD placement during the study period, but the charts for only 300 were available for review (the remaining 176 charts were either incomplete, missing, or had been destroyed due to flooding in 2001). Of the 300 available charts, 108 (36%) included VAD infection. The 108 infected patients had received 1 of 5 different types of VADs, including HeartMate IP ( ), HeartMate n p 34 XVE ( ), HeartMate II ( ), Thoratec ( ) (these n p 30 n p 23 n p 9 4 types of VADs were manufactured by Thoratec Corporation), and Jarvik ( ) (Jarvik Heart). n p 12 Infections. A total of 108 patients had VAD infections. Fifty-eight patients had a single VAD infection, 31 patients had 2 episodes, 13 patients had 3 episodes, and 6 patients had 4 episodes of VAD infection. Of all patients with 11 episode of infection, 28 (26%) had a recurrent infection with the same organism. The median time to diagnosis of a VAD infection from implantation was 36 days (interquartile range [IQR], 28-94.5 days). Of the 108 patients with a VAD infection, 85 had a bacterial VAD infection and 23 had a fungal infection (7 of 23 had a bacterial VAD infection that preceded the fungal VAD infection). There was no difference in time from VAD implantation to infection between the fungal and bacterial groups. Median duration of follow-up from the time of VAD implantation for patients with a bacterial VAD infection was 315 days (IQR, 150-1061 days) and for a fungal VAD infection was 130 days (IQR, 54-257 days;
). P p .007
The microbiologic findings are described in Table 1 . Grampositive bacteria accounted for 58.3%, gram-negative bacteria 26.8%, and fungal 14.8% of the total 209 microbiologic isolates. Common pathogens included Staphylococcus aureus (21.1%), coagulase-negative staphylococci (19.1%), enterococci (14.4%), and P. aeruginosa (10%). Twenty-three of the 108 (21%) patients had fungal infections, with Candida albicans being the most common fungal pathogen; 21.3% of infections were polymicrobial. Of all VAD infections, 46 (44.4%) involved the driveline, 34 (31.5%) affected the pocket, 57 (52.8%) involved the bloodstream, and 17 (15.7%) were associated with infective endocarditis. The relative distribution of these infections by bacterial and fungal groups is shown in Table 2 . Sixty-five percent of all fungal infections involved the bloodstream, whereas bacterial infections were more likely to involve the driveline than fungal infections (49.4% vs 26%;
). P p .046 Risk factors for fungal infection. As shown in Table 2 , factors significantly associated with the development of fungal VAD infection in univariate analysis included preoperative use of an intra-aortic balloon pump, receipt of total parenteral nutrition, longer operative time for the initial VAD surgery, greater number of blood transfusions, postoperative need for hemodialysis, greater number of invasive devices, and abdominal surgery. Multivariate analysis showed that only use of total parenteral nutrition was significantly associated with the development of a fungal VAD infection (odds ratio [OR], 6.95; 95% confidence interval [CI], 1.71-28.16;
). The as-P p .007 sociation of the number of invasive devices with fungal VAD infection trended toward significance (OR, 1.39; 95% CI, 0.98-1.96;
). P p .06 Fungal infections. Antifungal prophylaxis (generally with fluconazole) was administered to 70% of patients who subsequently developed fungal VAD infections and 65.5% of bacterial infections. The use of antifungal prophylaxis was unrelated to the development of a fungal VAD infection ( ). The rate P p .7 of fungal VAD infections prior to the routine use of antifungal prophylaxis was 6.6%, compared with 8% after the use of prophylaxis. We were unable to obtain details regarding antifungal susceptibilities of the fungal isolates. Patients with a fungal VAD infection were less likely to achieve a clinical and microbiological cure and had a greater number of infections, compared with those with bacterial infections (Table 3 ). More patients with fungal versus bacterial VAD infection died (91% vs 61%;
). Figure 1 illustrates the survival analysis of patients P p .006 with fungal and bacterial VAD infections.
Risk factors for death. Factors associated with all-cause mortality in univariate analysis were presence of a fungal VAD infection, VAD-related infective endocarditis, use of total parenteral nutrition, non-VAD related bloodstream infection, non-VAD related infection, and presence of diabetes mellitus. Multivariate analysis showed only the following independent risk factors to be significantly associated with mortality: fungal VAD infection (OR, 6.33; 95% CI, 1.33-30.06;
), presence of P p .02 a non-VAD-related infection (OR, 3.45; 95% CI, 1.38-8.65; ), and presence of diabetes mellitus (OR, 3.95; 95% P p .008 CI, 1.16-13.42;
). P p .028 DISCUSSION VAD infection is a relatively frequent and life-threatening complication [9, 11, 12] . The overall prevalence of VAD infection in this study was 36%, which falls within the wide range of 17.7%-72% that is reported elsewhere [9, [11] [12] [13] . The median time to diagnosis of VAD infection in our study was 36 days, similar to that described elsewhere [9] .
About one-half of VAD infections in this study were associated with a bloodstream infection, which occurred at a rate similar to that in one other report [9] but higher than that in another study [12] . In general, bloodstream infection leads to a higher rate of complications than seen with driveline or pocket infections alone. Because almost one-half of the infections were associated with the driveline, it is likely that the driveline was the major portal of entry for the infecting pathogens. Because VAD infections tend to clinically manifest early in the postoperative period, some infections may be due to perioperative inoculation of organisms, and thus, meticulous application of sterile surgical techniques would be essential for limiting the rates of infection. In addition, immobilization of the driveline, to minimize trauma, and daily cleansing and dressing exchange of the driveline exit site in the early postoperative stage are considered to be standard of care practices that are intended to decrease contamination and colonization of the device and, therefore, device-related infection. Antimicrobial coating or dipping of these devices, especially the driveline, in antimicrobial/antibiofilm solution has the potential of decreasing the incidence of early infection as well [14] .
Fungal VAD infections occurred in 7.6% of all 300 VAD recipients and accounted for 21% of all VAD infections (inclusive of 6.5% of patients that had a bacterial infection prior to development of a fungal VAD infection). One study performed in the era before routine antifungal prophylaxis noted that 35% of all VAD recipients developed a fungal VAD infection [15] .
Patients with VADs may have iatrogenic immunologic dysfunction that places them at an even higher risk of developing infection. The device induces an aberrant state of T cell activation that leads to programmed cell death among CD4-bearing T cells [16] . This results in defects in cellular immunity that may predispose to certain types of infection, including fungal infection. In a case-control study, the risk of developing disseminated candidiasis was found to be markedly increased (28% vs 3%; ) in VAD recipients versus control pa-P p .003 tients who received medical management of heart failure without VAD placement [17] .
Use of total parenteral nutrition is associated with candidemia in numerous study populations, including neonates, critically ill patients, and immunocompromised hosts [18] . In this study, we documented that use of total parenteral nutrition was the only risk factor in multivariate analysis that was associated with development of a fungal VAD infection. In fact, almost one-half of patients with fungal VAD infection had received total parenteral nutrition. Given the poor outcome of this infection, it is imperative that we optimize the nutritional status of VAD recipients via enteral feeding and avoid total parenteral nutrition.
Increased number of invasive devices trended toward significance in its association with fungal VAD infection. Other studies have shown that severity of illness, presence of central venous catheters, and the need for mechanical ventilation are all associated with invasive candidiasis [19, 20] . Extubation and removal of indwelling catheters and drainage tubes as soon as possible after device implantation may decrease the rate of fungal infection. Alternatively, duration of antifungal prophylaxis may need to be extended until all lines have been removed. Given the poor outcomes of fungal VAD infections, identification of risk factors is crucial for identification of factors that are amenable to manipulation and improvement before and after VAD implantation.
Approximately 70% of patients in our study had received antifungal prophylaxis with fluconazole; however, it did not appear to reduce the rate of fungal VAD infection. One study noted that continuation of antifungal prophylaxis until extubation and discontinuation of antibiotics was not cost-effective in VAD patients [21] . It may be reasonable to investigate the use of extended antifungal prophylaxis in VAD recipients until removal of all invasive devices or prophylaxis with agents other than fluconazole, such as echinocandins or amphotericin B.
An important finding of this study is the abysmal survival rate of patients who develop a fungal VAD infection. All-cause mortality was 91% in this population, and VAD infection-related mortality was 65%. An amalgation of various factors may play a role. This high mortality may reflect, at least in part, the general debilitation and poor immune status of patients that develop fungal VAD infection [17] . In other words, sicker patients tend to develop fungal infection and are also more likely to die from the infection. The high mortality may also be related to the difficulty in eradicating Candida species when present within the biofilm on the surface of devices. Studies have demonstrated drug resistance, especially to the azoles, by biofilmembedded Candida organisms grown on a variety of synthetic materials [22] . Use of amphotericin B lipid complex and caspofungin in animal models of vascular catheter infection have demonstrated significant decrease in biofilm fungal burden, and thus, these may be better options for the treatment of fungal VAD infection, rather than azoles [23, 24] .
We found that diabetes was associated with an increased risk of death regardless of the type of VAD infection. One study found that the presence of diabetes in VAD recipients was associated with an increased risk of developing VAD endocarditis, which in turn was associated with an increased risk of death versus other types of VAD infection [12] . Another series noted that diabetic patients were more likely to develop VAD-related bloodstream infection [9] . It is unclear at this point whether optimal blood sugar control in the perioperative period would lead to a decreased risk of infection or mortality and certainly opens up avenues for further research.
There are several limitations to our study. A large number of charts were unavailable for review because they were incomplete, missing, or destroyed via flooding. Because this was a retrospective chart review, there may be data-collection bias. We were also unable to abstract data regarding the specific number of antibiotic days as well as the exact duration of stay in the intensive care unit. Additionally, the fungal infection group contained 7 patients that had a bacterial infection prior to developing a fungal VAD infection. However, we conducted risk factor and outcome analysis with the exclusion of these patients with similar results (data not shown) and, thus, do not believe that inclusion of these patients has had significant impact on the results. Because this is a single center study, the results may not be generalizable to other centers.
In summary, fungi were responsible for approximately onefifth of VAD infections and were associated with high mortality. Because infection is the most common cause of death in patients with VADs, it is important to decrease the incidence of this complication and its consequences. Restriction of total parenteral nutrition use is essential in decreasing the rate of fungal VAD infection. Trials are needed for investigating the use of echinocandins or lipid formulations of amphotericin B for prevention and/or treatment of fungal VAD infection. By identifying and controlling risk factors, it is theoretically possible to reduce the occurrence of fungal VAD infection and/or increase the index of suspicion and treat such infections at an early stage. Such an approach may ameliorate outcomes, lead to clinical benefits, and incur sizable cost savings.
